Premium
WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER
Author(s) -
Stahel R.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_9
Subject(s) - pembrolizumab , nivolumab , medicine , atezolizumab , oncology , lung cancer , immunotherapy , clinical trial , ipilimumab , docetaxel , cancer , melanoma , cancer research